Skip to main content

Market Overview

Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis

Share:
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
  • A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary endpoints
  • Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are jointly developing dupilumab for many diseases.
  • The data showed Dupixent, when added to standard of care topical corticosteroids (TCS), significantly reduced overall disease severity and improved skin clearance, itch, and health-related quality of life measures at 16 weeks compared to TCS alone. 
  • Dupixent is the first biologic medicine to show positive results in this young population. 
  • It remains the only approved biologic medicine in patients 6 years and older with uncontrolled moderate-to-severe atopic dermatitis.
  • During the 16-week treatment period, Dupixent patients were 50% less likely to experience a skin infection (12% Dupixent, 24% placebo), and the total number of infections was nearly 70% lower (11 Dupixent, 34 placebo). 
  • 28% achieved clear or almost clear skin compared to 4% with placebo, the primary endpoint.
  • 53% achieved 75% or greater overall disease improvement from baseline compared to 11% with placebo, the co-primary endpoint outside of the U.S.
  • The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis. 
  • Price Action: REGN stock closed 0.37% lower at $663.29 on Friday, while SNY stock is up 0.31% at $51.99 during the premarket session on Monday's last check.
 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Posted-In: atopic dermatitis Briefs Phase 3 ResultsBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com